Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US
Introduction This study describes the frequency of prescription claims for drugs that may interact with Janus kinase (JAK) inhibitors among adult patients with rheumatoid arthritis (RA) in a large US claims database. Methods This observational, retrospective, cross-sectional study of the IBM ® Marke...
Gespeichert in:
| Veröffentlicht in: | Rheumatology and Therapy 2021-03, Vol.8 (1), p.599-607 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 607 |
|---|---|
| container_issue | 1 |
| container_start_page | 599 |
| container_title | Rheumatology and Therapy |
| container_volume | 8 |
| creator | Walton, Alison Paik, Jim Quebe, Amanda Kannowski, Carol L. Choong, Casey Anderson, Seth Owensby, Justin K. |
| description | Introduction
This study describes the frequency of prescription claims for drugs that may interact with Janus kinase (JAK) inhibitors among adult patients with rheumatoid arthritis (RA) in a large US claims database.
Methods
This observational, retrospective, cross-sectional study of the IBM
®
MarketScan
®
Research Commercial and the Medicare Supplemental Database included adults (≥ 18 years) with ≥ 2 outpatient claims 30 or more days apart or ≥ 1 inpatient visit claim with an RA diagnosis between January 1, 2013 and March 31, 2017 (the index period). During the study period, from January 1, 2013 to March 31, 2018, strong organic anion transporter (OAT3) inhibitors, strong cytochrome P450 (CYP) 3A4 inhibitors, and moderate or strong CYP3A4 inhibitors in combination with strong CYP2C19 inhibitors, were identified as drugs with potential for drug–drug interactions (DDIs) with JAK inhibitors approved for RA treatment in the US. Descriptive statistics were conducted.
Results
A total of 152,853 patients met eligibility criteria. Approximately 76% were women and the median age was 57 years. Of these patients, |
| doi_str_mv | 10.1007/s40744-020-00275-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7991043</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A656255320</galeid><sourcerecordid>A656255320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c541t-ef4008d970fe2329f95d2bc43139ee7bf50b997c8b21647ea5ef70d2c268ee673</originalsourceid><addsrcrecordid>eNp9Ud1uFCEYnRiNbda-gBeGxOupDDDA3Jhs1larNTZqrwnDfOzQ7MAKjGbfwYcWnbrqjeEC8p2fHL5TVU8bfN5gLF4khgVjNSa4xpiItpYPqlPSdLLmrWQPj2_BT6qzlO4wxg0nnEvxuDqhlEnGKD2tvl9G-DKDNwcULLqJkEx0--yCR5uddlNCNkT0Ks7bhPKoM3qvD-jKZ4jaZPTN5RG91X5O6J3zOkGBRte7HGJC6yn4LbrR2YHPaeF-HGGedA5uQOuYx-iyS8j5Yg3o9tOT6pHVuwRn9_equr28-Lx5U19_eH21WV_XpmVNrsEyjOXQCWyBUNLZrh1IbxhtaAcgetvivuuEkT1pOBOgW7ACD8QQLgG4oKvq5eK7n_sJBlPyRb1T--gmHQ8qaKf-Rbwb1TZ8VaLrGlz2tqqe3xvEULaXsroLc_QlsyKSi4aVVKSwzhfWVu9AOW9DMTPlDDA5EzxYV-Zr3nLStpTgIiCLwMSQUgR7jNRg9bN1tbSuSuvqV-tKFtGzvz9zlPzuuBDoQkgF8luIf8L-x_YHhUW6Dw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2867143292</pqid></control><display><type>article</type><title>Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US</title><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Springer Nature OA/Free Journals</source><creator>Walton, Alison ; Paik, Jim ; Quebe, Amanda ; Kannowski, Carol L. ; Choong, Casey ; Anderson, Seth ; Owensby, Justin K.</creator><creatorcontrib>Walton, Alison ; Paik, Jim ; Quebe, Amanda ; Kannowski, Carol L. ; Choong, Casey ; Anderson, Seth ; Owensby, Justin K.</creatorcontrib><description>Introduction
This study describes the frequency of prescription claims for drugs that may interact with Janus kinase (JAK) inhibitors among adult patients with rheumatoid arthritis (RA) in a large US claims database.
Methods
This observational, retrospective, cross-sectional study of the IBM
®
MarketScan
®
Research Commercial and the Medicare Supplemental Database included adults (≥ 18 years) with ≥ 2 outpatient claims 30 or more days apart or ≥ 1 inpatient visit claim with an RA diagnosis between January 1, 2013 and March 31, 2017 (the index period). During the study period, from January 1, 2013 to March 31, 2018, strong organic anion transporter (OAT3) inhibitors, strong cytochrome P450 (CYP) 3A4 inhibitors, and moderate or strong CYP3A4 inhibitors in combination with strong CYP2C19 inhibitors, were identified as drugs with potential for drug–drug interactions (DDIs) with JAK inhibitors approved for RA treatment in the US. Descriptive statistics were conducted.
Results
A total of 152,853 patients met eligibility criteria. Approximately 76% were women and the median age was 57 years. Of these patients, < 0.1% had a claim for a strong OAT3 inhibitor, and 1% had claims for the combination of a strong CYP3A4 and strong CYP2C19 inhibitor; 3% of patients had a claim for a strong CYP3A4 inhibitor and almost 10% had claims for both a moderate CYP3A4 and a strong CYP2C19 inhibitor.
Conclusions
Up to 10% of RA patients have been prescribed a drug with a potential JAK interaction. Rheumatologists should consider potential DDIs when managing patients with RA.</description><identifier>ISSN: 2198-6576</identifier><identifier>EISSN: 2198-6584</identifier><identifier>DOI: 10.1007/s40744-020-00275-8</identifier><identifier>PMID: 33484433</identifier><language>eng</language><publisher>Cheshire: Springer Healthcare</publisher><subject>Adverse and side effects ; Brief Report ; Drug therapy ; Drugs ; Family Medicine ; General Practice ; Internal Medicine ; Medicine ; Medicine & Public Health ; Orthopedics ; Prescribing ; Quality of Life Research ; Rheumatoid arthritis ; Rheumatology ; Statistics</subject><ispartof>Rheumatology and Therapy, 2021-03, Vol.8 (1), p.599-607</ispartof><rights>The Author(s) 2021</rights><rights>COPYRIGHT 2021 Springer</rights><rights>The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c541t-ef4008d970fe2329f95d2bc43139ee7bf50b997c8b21647ea5ef70d2c268ee673</citedby><cites>FETCH-LOGICAL-c541t-ef4008d970fe2329f95d2bc43139ee7bf50b997c8b21647ea5ef70d2c268ee673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991043/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7991043/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27924,27925,41120,42189,51576,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33484433$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Walton, Alison</creatorcontrib><creatorcontrib>Paik, Jim</creatorcontrib><creatorcontrib>Quebe, Amanda</creatorcontrib><creatorcontrib>Kannowski, Carol L.</creatorcontrib><creatorcontrib>Choong, Casey</creatorcontrib><creatorcontrib>Anderson, Seth</creatorcontrib><creatorcontrib>Owensby, Justin K.</creatorcontrib><title>Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US</title><title>Rheumatology and Therapy</title><addtitle>Rheumatol Ther</addtitle><addtitle>Rheumatol Ther</addtitle><description>Introduction
This study describes the frequency of prescription claims for drugs that may interact with Janus kinase (JAK) inhibitors among adult patients with rheumatoid arthritis (RA) in a large US claims database.
Methods
This observational, retrospective, cross-sectional study of the IBM
®
MarketScan
®
Research Commercial and the Medicare Supplemental Database included adults (≥ 18 years) with ≥ 2 outpatient claims 30 or more days apart or ≥ 1 inpatient visit claim with an RA diagnosis between January 1, 2013 and March 31, 2017 (the index period). During the study period, from January 1, 2013 to March 31, 2018, strong organic anion transporter (OAT3) inhibitors, strong cytochrome P450 (CYP) 3A4 inhibitors, and moderate or strong CYP3A4 inhibitors in combination with strong CYP2C19 inhibitors, were identified as drugs with potential for drug–drug interactions (DDIs) with JAK inhibitors approved for RA treatment in the US. Descriptive statistics were conducted.
Results
A total of 152,853 patients met eligibility criteria. Approximately 76% were women and the median age was 57 years. Of these patients, < 0.1% had a claim for a strong OAT3 inhibitor, and 1% had claims for the combination of a strong CYP3A4 and strong CYP2C19 inhibitor; 3% of patients had a claim for a strong CYP3A4 inhibitor and almost 10% had claims for both a moderate CYP3A4 and a strong CYP2C19 inhibitor.
Conclusions
Up to 10% of RA patients have been prescribed a drug with a potential JAK interaction. Rheumatologists should consider potential DDIs when managing patients with RA.</description><subject>Adverse and side effects</subject><subject>Brief Report</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Family Medicine</subject><subject>General Practice</subject><subject>Internal Medicine</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Orthopedics</subject><subject>Prescribing</subject><subject>Quality of Life Research</subject><subject>Rheumatoid arthritis</subject><subject>Rheumatology</subject><subject>Statistics</subject><issn>2198-6576</issn><issn>2198-6584</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp9Ud1uFCEYnRiNbda-gBeGxOupDDDA3Jhs1larNTZqrwnDfOzQ7MAKjGbfwYcWnbrqjeEC8p2fHL5TVU8bfN5gLF4khgVjNSa4xpiItpYPqlPSdLLmrWQPj2_BT6qzlO4wxg0nnEvxuDqhlEnGKD2tvl9G-DKDNwcULLqJkEx0--yCR5uddlNCNkT0Ks7bhPKoM3qvD-jKZ4jaZPTN5RG91X5O6J3zOkGBRte7HGJC6yn4LbrR2YHPaeF-HGGedA5uQOuYx-iyS8j5Yg3o9tOT6pHVuwRn9_equr28-Lx5U19_eH21WV_XpmVNrsEyjOXQCWyBUNLZrh1IbxhtaAcgetvivuuEkT1pOBOgW7ACD8QQLgG4oKvq5eK7n_sJBlPyRb1T--gmHQ8qaKf-Rbwb1TZ8VaLrGlz2tqqe3xvEULaXsroLc_QlsyKSi4aVVKSwzhfWVu9AOW9DMTPlDDA5EzxYV-Zr3nLStpTgIiCLwMSQUgR7jNRg9bN1tbSuSuvqV-tKFtGzvz9zlPzuuBDoQkgF8luIf8L-x_YHhUW6Dw</recordid><startdate>20210301</startdate><enddate>20210301</enddate><creator>Walton, Alison</creator><creator>Paik, Jim</creator><creator>Quebe, Amanda</creator><creator>Kannowski, Carol L.</creator><creator>Choong, Casey</creator><creator>Anderson, Seth</creator><creator>Owensby, Justin K.</creator><general>Springer Healthcare</general><general>Springer</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IAO</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20210301</creationdate><title>Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US</title><author>Walton, Alison ; Paik, Jim ; Quebe, Amanda ; Kannowski, Carol L. ; Choong, Casey ; Anderson, Seth ; Owensby, Justin K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c541t-ef4008d970fe2329f95d2bc43139ee7bf50b997c8b21647ea5ef70d2c268ee673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adverse and side effects</topic><topic>Brief Report</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Family Medicine</topic><topic>General Practice</topic><topic>Internal Medicine</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Orthopedics</topic><topic>Prescribing</topic><topic>Quality of Life Research</topic><topic>Rheumatoid arthritis</topic><topic>Rheumatology</topic><topic>Statistics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Walton, Alison</creatorcontrib><creatorcontrib>Paik, Jim</creatorcontrib><creatorcontrib>Quebe, Amanda</creatorcontrib><creatorcontrib>Kannowski, Carol L.</creatorcontrib><creatorcontrib>Choong, Casey</creatorcontrib><creatorcontrib>Anderson, Seth</creatorcontrib><creatorcontrib>Owensby, Justin K.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale Academic OneFile</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Rheumatology and Therapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Walton, Alison</au><au>Paik, Jim</au><au>Quebe, Amanda</au><au>Kannowski, Carol L.</au><au>Choong, Casey</au><au>Anderson, Seth</au><au>Owensby, Justin K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US</atitle><jtitle>Rheumatology and Therapy</jtitle><stitle>Rheumatol Ther</stitle><addtitle>Rheumatol Ther</addtitle><date>2021-03-01</date><risdate>2021</risdate><volume>8</volume><issue>1</issue><spage>599</spage><epage>607</epage><pages>599-607</pages><issn>2198-6576</issn><eissn>2198-6584</eissn><abstract>Introduction
This study describes the frequency of prescription claims for drugs that may interact with Janus kinase (JAK) inhibitors among adult patients with rheumatoid arthritis (RA) in a large US claims database.
Methods
This observational, retrospective, cross-sectional study of the IBM
®
MarketScan
®
Research Commercial and the Medicare Supplemental Database included adults (≥ 18 years) with ≥ 2 outpatient claims 30 or more days apart or ≥ 1 inpatient visit claim with an RA diagnosis between January 1, 2013 and March 31, 2017 (the index period). During the study period, from January 1, 2013 to March 31, 2018, strong organic anion transporter (OAT3) inhibitors, strong cytochrome P450 (CYP) 3A4 inhibitors, and moderate or strong CYP3A4 inhibitors in combination with strong CYP2C19 inhibitors, were identified as drugs with potential for drug–drug interactions (DDIs) with JAK inhibitors approved for RA treatment in the US. Descriptive statistics were conducted.
Results
A total of 152,853 patients met eligibility criteria. Approximately 76% were women and the median age was 57 years. Of these patients, < 0.1% had a claim for a strong OAT3 inhibitor, and 1% had claims for the combination of a strong CYP3A4 and strong CYP2C19 inhibitor; 3% of patients had a claim for a strong CYP3A4 inhibitor and almost 10% had claims for both a moderate CYP3A4 and a strong CYP2C19 inhibitor.
Conclusions
Up to 10% of RA patients have been prescribed a drug with a potential JAK interaction. Rheumatologists should consider potential DDIs when managing patients with RA.</abstract><cop>Cheshire</cop><pub>Springer Healthcare</pub><pmid>33484433</pmid><doi>10.1007/s40744-020-00275-8</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2198-6576 |
| ispartof | Rheumatology and Therapy, 2021-03, Vol.8 (1), p.599-607 |
| issn | 2198-6576 2198-6584 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7991043 |
| source | DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Springer Nature OA/Free Journals |
| subjects | Adverse and side effects Brief Report Drug therapy Drugs Family Medicine General Practice Internal Medicine Medicine Medicine & Public Health Orthopedics Prescribing Quality of Life Research Rheumatoid arthritis Rheumatology Statistics |
| title | Frequency of Prescription Claims for Drugs that May Interact with Janus Kinase Inhibitors Among Patients with Rheumatoid Arthritis in the US |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T07%3A55%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Frequency%20of%20Prescription%20Claims%20for%20Drugs%20that%20May%20Interact%20with%20Janus%20Kinase%20Inhibitors%20Among%20Patients%20with%20Rheumatoid%20Arthritis%20in%20the%20US&rft.jtitle=Rheumatology%20and%20Therapy&rft.au=Walton,%20Alison&rft.date=2021-03-01&rft.volume=8&rft.issue=1&rft.spage=599&rft.epage=607&rft.pages=599-607&rft.issn=2198-6576&rft.eissn=2198-6584&rft_id=info:doi/10.1007/s40744-020-00275-8&rft_dat=%3Cgale_pubme%3EA656255320%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2867143292&rft_id=info:pmid/33484433&rft_galeid=A656255320&rfr_iscdi=true |